Targeted drug trial aims to block cancer's growth signal in rare eye melanoma
NCT ID NCT03417739
Summary
This study tested an experimental drug called BVD-523 for people with advanced uveal melanoma, a rare eye cancer that had spread. The drug was designed to block a specific protein (ERK) that helps the cancer grow. The goal was to see if the drug could shrink tumors or stop them from progressing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.